Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

DBCOND0152726Male Urogenital Diseases Neoplasms

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as: Metastatic Hormone-sensitive Prostate Cancer · Metastatic Hormone Sensitive Prostate Cancer · Hormone Sensitive Metastatic Prostate Cancer
Classified under: Male Urogenital Diseases
Neoplasms
Urogenital Neoplasms
Indicated drugs: Abiraterone
Apalutamide

What you can answer from here — as of October 22, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

50Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account